Why Ivenix wants to create the next-generation of infusion pumps

Last month, medical device company Ivenix received clearance for a new smart infusion pump meant to address the safety issues endemic to the industry with more streamlined and intuitive technology.

Of the roughly 1.5 million adverse drug events are reported annually to the FDA, more than half are attributed to infusion-related errors.

The automated pumps that deliver medication to patients have a higher risk and severity of error than other types of medication administration and have been linked to many instances of patient injury or death because of incorrect dosing due to human or software error.

Last month, medical device company Ivenix received clearance for a new smart infusion pump meant to address the safety issues endemic to the industry with more streamlined and intuitive technology.

The company received its clearance after three years under the more stringent FDA guidelines required as part of the agency’s increased oversight of the industry.

Ivenix has been at the problem for a long time. Initially founded as Fluidnet Corp. back in 2001, the company has raised around $90 million on the road to its regulatory approval.

Read the Full Article